Revenio Group Oyj (HEL:REG1V)
Finland
· Delayed Price · Currency is EUR | Market Cap | 377.26M |
| Revenue (ttm) | 109.85M |
| Net Income (ttm) | 17.41M |
| Shares Out | 26.61M |
| EPS (ttm) | 0.65 |
| PE Ratio | 21.67 |
| Forward PE | 15.31 |
| Dividend | 0.44 (2.76%) |
| Ex-Dividend Date | Apr 11, 2025 |
| Volume | 327,234 |
| Average Volume | 82,089 |
| Open | 15.70 |
| Previous Close | 15.94 |
| Day's Range | 14.08 - 15.70 |
| 52-Week Range | 14.08 - 29.80 |
| Beta | 1.05 |
| RSI | 23.15 |
| Earnings Date | Apr 28, 2026 |
About Revenio Group Oyj
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by vet... [Read more]
Financial Performance
In 2025, Revenio Group Oyj's revenue was 109.85 million, an increase of 5.80% compared to the previous year's 103.82 million. Earnings were 17.41 million, a decrease of -5.87%.
Financial StatementsNews
Revenio Group Oyj Transcript: M&A announcement
The merger creates a leading ophthalmic diagnostics company with a EUR 2.5 billion accessible market, targeting EUR 20 million in synergies and 25% EBITDA margin by 2028-2029. Integration is structured for rapid synergy capture, with strong shareholder and leadership commitment.
Revenio Group Oyj (STU:R0V) Full Year 2025 Earnings Call Highlights: Strong Sales Growth Amidst ...
Revenio Group Oyj (STU:R0V) Full Year 2025 Earnings Call Highlights: Strong Sales Growth Amidst Profitability Challenges
Full Year 2025 Revenio Group Oyj Earnings Call Transcript
Full Year 2025 Revenio Group Oyj Earnings Call Transcript
Revenio Group Oyj Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw strong sales growth, record US performance, and robust cash flow, despite margin pressure from tariffs and delayed price increases. 2026 guidance anticipates 8%-15% sales growth, with profitability supported by ongoing price adjustments and a strong product pipeline.
Revenio Group Oyj (REVXF) Q3 2025 Earnings Call Highlights: Strong European Growth and ...
Revenio Group Oyj (REVXF) Q3 2025 Earnings Call Highlights: Strong European Growth and Strategic US Launches Amid Currency Challenges
Q3 2025 Revenio Group Oyj Earnings Call Transcript
Q3 2025 Revenio Group Oyj Earnings Call Transcript
Revenio Group Oyj Earnings Call Transcript: Q3 2025
Q3 delivered 8.1% sales growth and 9.1% higher operating profit, led by strong European and U.S. performance in screening devices and software. Guidance remains unchanged, with Q4 expected to be the strongest quarter. New product launches and robust financials support a positive outlook.
Revenio Group Oyj Earnings Call Transcript: Q2 2025
Q2 saw 4.2% reported sales growth (7.2% currency-adjusted), with all regions and product categories contributing. Gross margin exceeded 70%, and adjusted operating profit rose ~10% in Q2. Tariff impacts are being managed with planned price increases as inventory runs out.
Revenio Group Oyj Earnings Call Transcript: Q1 2025
Q1 2025 saw strong organic growth across all regions and product lines, with net sales up 10.5% and EBIT margin at 25.4%. U.S. tariffs and FX volatility pose risks, but price increases and natural hedging are in place. Guidance targets 6%-15% sales growth and stable profitability.
Revenio Group Oyj Earnings Call Transcript: Q4 2024
Q4 and full-year 2024 saw strong sales growth, robust profitability, and record cash flow, driven by new product launches and recurring revenue. Guidance for 2025 anticipates 6%-15% sales growth, with profitability remaining strong despite geopolitical and regulatory risks.
Revenio Group Oyj Earnings Call Transcript: Q3 2024
Q3 saw 8.9% net sales growth (15.1% FX-adjusted), strong product launches, and robust performance in imaging and tonometer segments. FX headwinds and higher marketing costs impacted margins, but full-year sales are expected to surpass EUR 100 million.
Revenio Group Oyj Earnings Call Transcript: Q2 2024
Q2 net sales grew 14.2% year-over-year, driven by strong performance in fundus imaging and tonometers, with stable margins and robust cash flow. Guidance for 2024 remains at 5%-10% net sales growth, with profitability expected to stay strong. Clinical trial costs and an off-balance sheet contingent liability are key uncertainties.